TANDEARIL
LOE ApproachingNDAORALTABLET
Approved
Dec 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TANDEARIL is an oral small-molecule tablet approved by Novartis in 1960 with an unknown mechanism of action and indication profile. The drug's mechanism and therapeutic area remain undocumented in available data, limiting clinical characterization.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating likely portfolio defense or planned transition activities within the commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job count reflects TANDEARIL's mature, legacy status with minimal current hiring. Career opportunity on this product is primarily in portfolio management, generic transition planning, and cost-containment strategies rather than growth-focused roles.
Brand ManagerCommercial Operations Analyst
Worked on TANDEARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.